Last reviewed · How we verify

Exelon (rivastigmine) — Competitive Intelligence Brief

Exelon (rivastigmine) (Exelon (rivastigmine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor. Area: Neurology.

marketed Cholinesterase inhibitor Acetylcholinesterase and butyrylcholinesterase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Exelon (rivastigmine) (Exelon (rivastigmine)) — Singapore General Hospital. Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase enzymes, increasing acetylcholine levels in the brain to improve cognitive function in dementia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Exelon (rivastigmine) TARGET Exelon (rivastigmine) Singapore General Hospital marketed Cholinesterase inhibitor Acetylcholinesterase and butyrylcholinesterase
Rivastigmine patch Rivastigmine patch Chung-Ang University Hosptial, Chung-Ang University College of Medicine marketed Cholinesterase inhibitor Acetylcholinesterase and butyrylcholinesterase
Rivastigmine Patch 9.5 cm2 Rivastigmine Patch 9.5 cm2 University of California, San Francisco marketed Cholinesterase inhibitor Acetylcholinesterase and butyrylcholinesterase
Rivastigmine 5 cm^2 transdermal patch Rivastigmine 5 cm^2 transdermal patch Novartis phase 3 Cholinesterase inhibitor Acetylcholinesterase and butyrylcholinesterase
Bloxiverz NEOSTIGMINE Fresenius Kabi marketed Cholinesterase Inhibitor Acetylcholinesterase 2013-01-01
Razadyne GALANTAMINE Johnson & Johnson marketed Cholinesterase Inhibitor Acetylcholinesterase 2001-01-01
Aricept DONEPEZIL Eisai marketed Cholinesterase Inhibitor Sigma non-opioid intracellular receptor 1 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase inhibitor class)

  1. Novartis · 3 drugs in this class
  2. Eisai Co., Ltd. · 1 drug in this class
  3. Icure Pharmaceutical Inc. · 1 drug in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Pfizer · 1 drug in this class
  7. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
  8. Singapore General Hospital · 1 drug in this class
  9. Sunnybrook Health Sciences Centre · 1 drug in this class
  10. Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exelon (rivastigmine) — Competitive Intelligence Brief. https://druglandscape.com/ci/exelon-rivastigmine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: